Brief: Heat Biologics Plans To Initiate Type B End Of Phase 2 Meeting With FDA To Discuss Registration Strategy For Hs-110
11/05/2020 13:54
May 11 (Reuters) - Heat Biologics Inc HTBX.O :
* HEAT BIOLOGICS INC - PLAN TO INITIATE TYPE B END OF PHASE
2
MEETING WITH FDA TO DISCUSS REGISTRATION STRATEGY FOR HS-110
Source text for Eikon: ID:nNDL4nm7P0
Further company coverage: HTBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scorpius Holdings
See all newsBrief: Scorpius Holdings Inc Files For Non Timely 10-K With U.S. SEC
Brief: Scorpius Holdings Files For Offering Up To 29.4 Million Shares Of Common Stock
Brief: Scorpius Holdings Announces Collaboration With Celltheon Corporation
Brief: Scorpius Holdings - Implementation Of Strategic Cost-Saving Measures Expected To Save Over $2 Mln Annually
Brief: Scorpius Holdings Announces Partnership With U.S. Biotech Company